MetaCap

Janux Therapeutics (JANX) vs First Tracks Biotherapeutics (TRAX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Janux Therapeutics is the larger company by market cap ($1.10 billion vs $1.09 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JANX+19.95%TRAX+61.00%
+161%+66%-28%
Apr 6, 20261 yearOct 7, 2026
JANX+20.03%TRAX+30.17%
+99%+30%-38%
Apr 6, 20265 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JANX versus TRAX key metrics
MetricJANXTRAX
Share price$17.92$30.59
Market cap$1.10B$1.09B
1-day change+6.73%-2.55%
YTD return+29.86%—
1-year return-21.02%—
5-year return-15.19%—
EPS (TTM)$-1.64$-4.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$35.34$49.91
52-week low$12.12$14.72
Distance from 52-week high-49.29%-38.71%
Average volume830.67K792.69K
Shares outstanding61.14M35.73M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

JANX vs TRAX FAQ

Which is bigger, Janux Therapeutics or First Tracks Biotherapeutics?

Janux Therapeutics (JANX) is larger, with a market capitalization of $1.10B compared with $1.09B for First Tracks Biotherapeutics (TRAX).

Are Janux Therapeutics and First Tracks Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons